Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

PRESS: U.S. IPOs Drag, Weighed Down by Brexit, Other Uncertainty <i>(Bloomberg BNA)</i>

PRESS: U.S. IPOs Drag, Weighed Down by Brexit, Other Uncertainty (Bloomberg BNA)

Related Content

Nasdaq Adopts Enhanced SPAC IPO Listing Standards Under Both Global Market and Capital Market Tiers

Intellia Initiates Rolling BLA Submission for In Vivo CRISPR Therapy in Hereditary Angioedema

Federal Circuit Reverses JMOL and Reinstates Jury Verdict in Teva v. Lilly

FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars

Biocon Launches Denosumab Biosimilars

FDA Approves First Gene Therapy for Rare Pediatric Immune Disorder Severe Leukocyte Adhesion Deficiency Type I

FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)

Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar

Goodwin Advises Apnimed on Securing Up to $150 Million in Debt Financing with HealthCare Royalty Partners

Goodwin Guides Apnimed on Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150 Million and Royalties

Goodwin Guides Nektar Therapeutics on its $373.8 Million Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Goodwin Advises CathWorks on $585 Million Acquisition by Medtronic

Goodwin Advises Kelonia Therapeutics in Acquisition by Lilly for $7 Billion, Largest In-Vivo CAR-T Deal to Date

Goodwin Advises Obsidian Therapeutics on Merger With Galera Therapeutics and $350 Million Private Placement Financing

Weight-Loss Drug M&A Engorges Deal Values in 2025, Driven by Fat Cheque for Metsera – Dealspeak EMEA (Mergermarket)

Goodwin Guides Piramal on Acquisition of Kenalog®

Life Sciences

Technology

Capital Markets

Public Company Advisory Practice